- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02759549
Fatigue in Breast Cancer Patients Undergoing Radiotherapy-eSMART-MH
Fatigue in Breast Cancer Patients Undergoing Radiotherapy-Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
The purpose of this study is to determine if an avatar-based depression self-management intervention (eSMART-MH) once a week for the duration of the participant's radiation treatment will significantly reduce depressive symptoms. Investigators also seek to explore how women with breast cancer describe their mood using prompted and unprompted speech through electronic social media and interviews.
Participants will be randomized into the eSMART-MH group or the theater testing (attention control) group. In addition to the assigned interventions, participants will be asked to complete questionnaires and interviews with the study staff.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine if an avatar-based depression self-management intervention (eSMART-MH) once a week for the duration of the participant's radiation treatment will significantly reduce depressive symptoms. Investigators also seek to explore how women with breast cancer describe their mood using prompted and unprompted speech through electronic social media and interviews.
Participants will be randomized into the eSMART-MH group or the theater testing (attention control) group. In addition to the assigned interventions, participants will be asked to complete questionnaires and interviews with the study staff.
Participants will be enrolled within two weeks of radiotherapy. A preliminary depression survey (IDS-SR) will be given to assess depression. There will be a total of three routine study assessments, one within two weeks prior to the beginning of radiotherapy, one the last week of radiotherapy and one 5 - 7 weeks after radiotherapy is completed.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
Atlanta, Georgia, United States, 30322
- Emory Clinic
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital Midtown
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients seen in the Emory Breast Center at The Emory Clinic and Emory Midtown Hospital who are treated with curative intent.
- Score of 8 or higher on the Inventory of Depressive Symptomology - Self Reported (IDS-SR) test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: eSMART-MH
Participants undergoing radiation treatment for breast cancer will receive the Electronic Self-Management Resource Training for Mental Health (eSMART-MH) intervention.
|
eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach).
The avatars are programmed to behave like humans.
The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers.
The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach.
The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit.
eSMART-MH will be used once a week throughout the duration of radiation treatment.
Public social media data posted by participants will be accessed and downloaded to a computer program.
Permission for the study team to access this data is optional.
|
|
Other: Theater Testing
Participants undergoing radiation treatment for breast cancer will participate in a theater testing workshop.
|
The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement.
Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in an Inventory of Depressive Symptomatology-Self Reported (IDS-SR) score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The IDS-SR is a self-reported measure in which participants rate the frequency of depression symptoms within the past seven days.
Scores range from 0 to 84, with higher score reflecting greater severity of depressive symptoms.
|
Baseline, Post Treatment (5-7 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pittsburgh Sleep Quality Index (PSQI) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
Scores range from 0 to 21.
A score of less than or equal to 5 is associated with good sleep quality.
A score greater than 5 is associated with poor sleep quality.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Perceived Stress Scale (PSS) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The PSS is a self-reported instrument used to measure the perception of stress.
Scores range from 0 to 40.
Score of 20 or higher are considered high stress.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Short Form-36 (SF-36) Health Survey Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The SF-36 is a self-reported survey of health status.
Scores range from 0 to 100.
Lower scores indicate disability.
The higher the score, the less disability.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Godin Leisure-Time Exercise Questionnaire (GLTEQ) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The GLTEQ is a self-reported questionnaire used to measure usual leisure-time exercise habits during a typical seven day period.
A score of 24 or more indicates active and substantial exercise benefits.
A score of 23 units or less indicates insufficiently active and less substantial exercise benefits.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The PROMIS Fatigue questionnaire is a self-report tool used to evaluate frequency, duration, and intensity of fatigue over the past seven days.
Scores range from 7 to 35.
The higher the score, the more fatigue.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Lent Soma Scale Patient Questionnaire Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The Lent Soma questionnaire is a self-reported measure of pain.
Scores range from 0 to 9. The higher the score, the more pain reported.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Multidimensional Fatigue Inventory (MFI) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue.
Scores range from 20 to 100.The higher the score, the more fatigued.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in The Centers for Disease Control (CDC) Health-Related Quality of Life-4 (QOL) Questionnaire Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
Quality of Life will be measured by the Center for Disease Control Health Related Quality of Life-4 (CDC HRQOL).
This self-report measures quality of life over the last 30 days in the domains of physical and mental health.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Functional Assessment of Cancer Therapy-General (FACT-G) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The FACT-G is a self-reported measure of well being in the past seven days.
Scores range from 0 to 27.
A higher score indicates worse perception of well being.
|
Baseline, Post Treatment (5-7 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Behavioral Activation for Depression Scale-Short Form (BADS-SF) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The BADS-SF is a 9-item self-report measures that assess behavioral activation which captures the domains of activation, avoidance/rumination, work/school impairment, and social impairment.
The BADS-SF asks participants to respond to each statement over the past week, including the day in which they complete the measure, on a 0 to 6 likert type scale.The BADS-SF has shown to be significantly associated with depression.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Self-Efficacy for Managing Chronic Disease 6-Item Scale Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The Self-Efficacy for Managing Chronic Disease questionnaire is a six item self-report scale.
This measure asks how confident, on a scale of 1-10, the respondent is in doing certain activities pertaining to self-management.
Scores range from 6 to 60.
A higher score indicates more confidence.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Pediatric CARE measure 10 questions (PCM 10Q) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The PCM 10Q is used to gain the views of children or patients receiving health services.
It is a patient-centered measure of relational empathy.
It measures patients' experiences of the interpersonal aspects of clinical encounters.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Virtual Support Measure Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The virtual support questionnaire is a measure of perceived virtual support of the avatars.
Participants rate the "virtual support" provided by the avatar healthcare provider and avatar coach separately.
The first 12 questions of the Virtual Support Questionnaire ask participants to rate, on a Likert-type format, the avatars on a variety of relational characteristics.
Selection options range from (1) "No, not at all" to (5) "Yes, definitely."
The last 10 items of the Virtual Support Questionnaire ask respondents to rate, using a Likert-type format, to what degree they agree or disagree with statements about how the avatars understood their experiences.
Selection options ranged from (1) "Strongly agree" to (6) "Strongly disagree."
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in The University of California, Los Angeles (UCLA) Loneliness Scale Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The UCLA Loneliness Scale is a 20-item scale designed to measure one's subjective feelings of loneliness as well as feelings of social isolation.
Participants rate each item as either O ("I often feel this way"),S ("I sometimes feel this way"), R ("I rarely feel this way"), N ("I never feel this way").
A higher score indicates more feelings of loneliness.This scale has a strong association with depression.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Patient Activation Measure (PAM-13) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The PAM-13 is a 13-item measure that assesses the patient's perception of their knowledge, skill, and confidence in self-management behavior.
Scores range from 0-100, with a higher score indicating greater patient activation.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Quality of Patient-Provider Interaction Questionnaire (QPPI) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The QPPI is a 14-item self-report likert type style questionnaire that assesses from the patient's perspective the quality of the interaction between the patient provider.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Patient Self-Competence Subscale (PSCS) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
A 16-item five point Likert scale that asks participants to rate items from 5 (important) to 1 (unimportant); a higher score indicates greater perceived self-competence and effective communication with a health care provider.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in FAS Verbal Fluency Test Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The FAS Verbal Fluency Test task asks respondents to generate words beginning with the letters "F," "A," and "S" within 60 seconds.
Adults with depression generate fewer words on the FAS than non-depressed.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in The State Hope Scale Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The State Hope Scale is a a 6-item self-report scale which measures goal-directed thinking and the "here and now."
Respondents are asked to respond to items in relation to what is "going on in your life right now" in response to goal-directed statements on a 1-8 scale.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Emotional Regulation Questionnaire (ERQ) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The ERQ is a 20-item scale that asks respondents how they manage and regulate their emotions in response to life events on a 1-7 likert-type scale.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Body Awareness Questionnaire Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The Body Awareness Questionnaire is a an 18-item measure that asks respondents to rate their sensitivity to normal and non-emotional body processes on a 1-7 likert-type scale.
|
Baseline, Post Treatment (5-7 weeks)
|
|
Change in Experiences Questionnaire (EQ) Score
Time Frame: Baseline, Post Treatment (5-7 weeks)
|
The EQ is a 20 item self-report scale designed to measure decentering and deep thinking.
|
Baseline, Post Treatment (5-7 weeks)
|
|
3 Item Functional Health Literacy Quick Screen
Time Frame: Baseline
|
The 3 Item Functional Health Literacy Quick Screen is used to detect limited and marginal health literacy skills.
|
Baseline
|
|
Tobacco Use Questionnaire
Time Frame: Baseline
|
The Tobacco Use Questionnaire is two question self-report about the use of traditional cigarettes, or e-cigarettes, or both and the amount of cigarettes smoked.
|
Baseline
|
|
Alcohol Use Disorders Identification Test (AUDIT)
Time Frame: Baseline
|
The AUDIT simple brief assessment tool to screen for excessive drinking.
The measure consists of 10 questions about recent alcohol use, alcohol dependence symptoms, and alcohol-related problems.
|
Baseline
|
|
Adverse Childhood Event (ACE) Questionnaire
Time Frame: Post last intervention (4 week follow up)
|
An ACE score is a tally of different types of abuse, neglect, and household dysfunction.
There are 10 items on the measure; we will ask 9 of these questions, omitting the question about sexual abuse.
The ACE Study emphasizes the number rather than categories of ACE that one has been subjected to.
The number of the nine items of ACE that one has undergone (0-9) is regarded as the ACE score.
|
Post last intervention (4 week follow up)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00028295
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on eSMART-MH
-
Case Western Reserve UniversityCompletedDepression | Generalized Anxiety DisorderUnited States
-
Emory UniversityWithdrawnDepression | HIV
-
3-C Institute for Social DevelopmentNational Institute of Mental Health (NIMH)CompletedMental Health Strategies | School Mental Health Services | Digital Technologies | Technology DevelopmentUnited States
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); New York City Department for the...Completed
-
VA Office of Research and DevelopmentCompletedPsychotic Disorders | Mood Disorders | Stress Disorders, Post-TraumaticUnited States
-
Children's Hospital Medical Center, CincinnatiNational Institute of Mental Health (NIMH)RecruitingMental Health Disorder | Family Navigation | Minoritized Population | Preschool Age ChildrenUnited States
-
VA Office of Research and DevelopmentCompletedMental Health | Healthcare DisparitiesUnited States
-
Vespina Lifesciences Inc.Syneos Health; PrimeVigilance Ltd., UKCompleted
-
Assistance Publique Hopitaux De MarseilleUnknownEvaluate Both Technics on Procedure Duration | Characteristics and Perioperative ComplicationsFrance
-
El Instituto Nacional de Neurologia y Neurocirugia...Completed